Medical Condition News

RSS

Case Western Reserve University researchers step up to National Institutes of Health challenge

Futuristic plans to grow replacement organs, bones or muscles for soldiers maimed on the battlefield or patients suffering from debilitating disease or injury won't be anything but science fiction unless new blood vessels can grow into that tissue

14 Oct 2009

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).

14 Oct 2009

Timely and individualized publicly funded therapy denied to children with autism

With October being Autism Awareness Month in Canada, Ontarians should be aware of the increasingly large gaps in services for children with autism in this province.

14 Oct 2009

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

The National Institutes of Health (NIH) has awarded a "Grand Opportunity" grant of $3.7 million to a consortium formed with the Gladstone Institute of Neurological Disease (GIND) and the Taube-Koret Center for Huntington's Disease Research to use stem cell technology to better understand Huntington's disease (HD) and to develop potential therapies.

14 Oct 2009

Bioluminescence imaging distinguishes tumor growth in vivo; leads to early treatment of eye cancer

At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.

14 Oct 2009

Positive results from Alkermes' ALKS 33 clinical trials announced

Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.

13 Oct 2009

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Meda Pharmaceuticals Inc. today announced the launch of Onsolis(TM)(fentanyl buccal soluble film) in the U.S. for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

13 Oct 2009

PhysioNetics receives grant to continue development of 'gripper' for upper-extremity prostheses

A $750,000 Phase II grant from the National Institutes of Health will allow PhysioNetics, LLC to continue its development work on an innovative new “gripper” for upper-extremity prostheses.

13 Oct 2009

Interleukin Genetics to present new genetic findings on obesity and osteoporosis

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it will present new genetic findings in the fields of obesity and osteoporosis at medical meetings later this month.

13 Oct 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.

13 Oct 2009

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Compugen Ltd. announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany covering the further evaluation of a Compugen discovered tumor target and its splice variants.

13 Oct 2009

Cochlear implant inventor chosen for neuroscience research

Dr. Michael Merzenich, PhD - renowned neuroscientist, university professor, cochlear implant inventor, brain plasticity expert and tech entrepreneur - was formally inducted in the Institute of Medicine (IOM) today in Washington, D.C.

13 Oct 2009

University of Nottingham pioneers new type of MRI scan

People with chronic lung disease and asthma could soon be offered better treatment thanks to a new type of Magnetic Resonance Imaging (MRI) scan being pioneered at The University of Nottingham.

13 Oct 2009

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

People with psoriasis and/or psoriatic arthritis who are taking biologic or non-biologic immunosuppressive medications should receive the inactived forms of both seasonal influenza and H1N1 (swine flu) vaccines as soon as possible, according to a recommendation from the National Psoriasis Foundation.

13 Oct 2009

AHA: Americans should reduce their calorie intake to combat obesity and cardiovascular disease

Reaching for that chocolate chip cookie? Think twice. The American Heart Association (AHA) just released the strictest guidelines ever for added sugars, recommending Americans limit their diet to 100 calories (6 teaspoons) for women and 150 calories (nine teaspoons) for men each day.

13 Oct 2009

Discovery opens new possibility of designing drugs for amyotrophic lateral sclerosis

Researchers at Lund University, Sweden, have taken a snapshot of proteins changing shape, sticking together and creating structures that are believed to trigger deadly processes in the nervous system. The discovery opens the possibility of designing drugs for a devastating neurological disease, ALS.

13 Oct 2009

9% of Québec adults report being diagnosed with a thyroid disease

New research reveals 9 percent of Québec adults report being diagnosed with a thyroid disease. The thyroid gland produces the hormones that regulate our growth, maturation, speed of metabolism and sensitivity to other hormones.

13 Oct 2009

New study launched to detect DNA alterations linked to sudden cardiac death in sports

The BBVA Foundation and the Cardiology Service of Madrid's Hospital Clínico San Carlos have launched a new study aimed at detecting DNA alterations linked to sudden cardiac death in sports. Genetic testing is vital if the condition is to be caught in time, since most cases are asymptomatic and hard to diagnose by other means.

13 Oct 2009

Good Samaritan Hospital tops HealthGrade ratings for stroke treatment and joint replacement

A study issued today by HealthGrades, Inc., the leading independent healthcare ratings organization, finds that Good Samaritan Hospital is among the Top 5% in the Nation for Treatment of Stroke and Top 10% in the Nation for Joint Replacement. The nation’s nearly 5,000 nonfederal hospitals were all included in the sweeping study, which examined mortality rates and complication rates from government data from 2006, 2007 and 2008.

13 Oct 2009

New mouse models resembles human ALS; may provide important tool for screening new drugs

A new mouse model of amyotrophic lateral sclerosis (ALS) closely resembles humans with the paralyzing disorder, researchers at Washington University School of Medicine in St. Louis report.

13 Oct 2009

Medical Condition News

Case Western Reserve University researchers step up to National Institutes of Health challenge

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

Timely and individualized publicly funded therapy denied to children with autism

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

Bioluminescence imaging distinguishes tumor growth in vivo; leads to early treatment of eye cancer

Positive results from Alkermes' ALKS 33 clinical trials announced

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

PhysioNetics receives grant to continue development of 'gripper' for upper-extremity prostheses

Interleukin Genetics to present new genetic findings on obesity and osteoporosis

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Cochlear implant inventor chosen for neuroscience research

University of Nottingham pioneers new type of MRI scan

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

AHA: Americans should reduce their calorie intake to combat obesity and cardiovascular disease

Discovery opens new possibility of designing drugs for amyotrophic lateral sclerosis

9% of Québec adults report being diagnosed with a thyroid disease

New study launched to detect DNA alterations linked to sudden cardiac death in sports

Good Samaritan Hospital tops HealthGrade ratings for stroke treatment and joint replacement

New mouse models resembles human ALS; may provide important tool for screening new drugs

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News